Back to top
more

ASLAN Pharmaceuticals (ASLN)

(Delayed Data from NSDQ)

$0.45 USD

0.45
292,541

-0.01 (-2.78%)

Updated May 3, 2024 04:00 PM ET

After-Market: $0.44 -0.01 (-1.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus

by Zacks Equity Research

Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.

CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.

Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.

Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer

by Zacks Equity Research

The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.

vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.

What Makes ASLAN Pharmaceuticals Ltd. (ASLN) a New Buy Stock

by Zacks Equity Research

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study

by Zacks Equity Research

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

by Zacks Equity Research

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program

by Zacks Equity Research

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs

by Zacks Equity Research

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress

by Zacks Equity Research

Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU

by Zacks Equity Research

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.

Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate

by Zacks Equity Research

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data

by Zacks Equity Research

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU

by Zacks Equity Research

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

Novartis (NVS) to Acquire Neuroscience Company for Up to $770M

by Zacks Equity Research

Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.

Ultragenyx (RARE) Gets Orphan Drug Tag for Wilson Disease Drug

by Zacks Equity Research

Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.

CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab

by Zacks Equity Research

CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.

Intellia (NTLA) Catches Eye: Stock Jumps 7.8%

by Zacks Equity Research

Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA

by Zacks Equity Research

The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.

Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA

by Zacks Equity Research

Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.